Exocrine pancreatic insufficiency (EPI) is a disorder related to a lack of exocrine pancreatic enzymes which result in the incapability of digesting meals or maldigestion. EPI is also linked with several pancreatic conditions such as chronic pancreatitis, cystic fibrosis, and Schwachman–Diamond syndrome. EPI’s most common cause is chronic pancreatitis (CP) in the adult population. After that, cystic fibrosis (CP) also causes EPI. It is an inherited hereditary disorder that guides to a chronic condition, which affects the respiratory, digestive, and reproductive systems. Patients of EPI have a hard time digesting fats, proteins, and carbohydrates. It leads to weak nutrient absorption in the body.
Get PDF Sample Copy (Including Full TOC, List of Tables & Figures, Chart) @
https://www.coherentmarketinsights.com/insight/request-sample/2020
Likewise, EPI displays some gastrointestinal irritations (GI) such as bloating, diarrhea, and gas. The symptoms of EPI appear the same as other gastrointestinal conditions such as irritable bowel syndrome (IBS), celiac disease, small intestinal bacterial overgrowth (SIBO), Crohn’s disease, and ulcerative colitis, which creates difficulties in the diagnosis of EPI. Still, there are three common tests available in the market for the diagnosis of EPI, are direct pancreatic function test, fecal fat test, and fecal elastase test.
EPI occurs during significant disorders such as autoimmune pancreatitis, celiac disease, cystic fibrosis, gastrointestinal surgery, inflammatory bowel disorder, pancreatectomy, pancreatic cancer, regular pancreatitis, and type I and III C diabetes. Even though, raised majority of these conditions tend to develop EPI, which improvises the growth of the exocrine pancreatic insufficiency (EPI) therapeutics market. Based on the report posted in 2010, by the Cystic Fibrosis Foundation, every year almost 1,000 new cases of cystic fibrosis occurred worldwide.
Likewise, based on the report published in 2010, by the American Lung Association, in the American market, cystic fibrosis is the second most inherited condition in newborns. The report also displays that approximately 10 million patients in the American market stand symptomless runners of the deficient cystic fibrosis gene, and almost 3,700 casualties occurred due to cystic fibrosis between 1999 and 2006. Pancreatic cancer is the main element that guides EPI. Based on the report published in 2015, by Cancer Research UK, from 2013 to 2015, roughly 9,800 pancreatic cancer patients were documented in the United Kingdom. It also noted that pancreatic cancer accounts for 3% of all new cancer cases in the U.K., in 2015.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/2020
Based on the report posted in 2018, by Diabetes.co.uk, EPI stands to be more prominent in individuals with insulin-dependent diabetes. In 2003, an investigation performed on roughly 1,000 diabetic patients discovered that insulin-dependent diabetes will produce abnormally lower grades of exocrine pancreatic enzymes. Likewise, between 25-30% of insulin-dependent diabetes cases were generated exocrine pancreatic insufficiency. Moreover, an elevated majority of diabetes may boost the chance of EPI.
Based on geography, the international EPI therapeutics market had divided into Africa, Asia Pacific, the Middle East, Latin America, North America, and Europe. The North American market has a principal place in the global EPI therapeutics market. It occurs due to the rising incidence and majority topics of these situations happening in the regional market. The EPI is commonly represented by its associated disorders such as chronic pancreatitis, cystic fibrosis, gastrointestinal surgery, pancreatic cancer, and others.
Competitive Analysis:
Major companies working in the exocrine pancreatic insufficiency (EPI) therapeutics market have AbbVie, Inc., AzurRx BioPharma, Inc., Allergan plc, Anthera Pharmaceuticals, Inc., Digestive Care, Inc., and others. Major companies working in the exocrine pancreatic insufficiency (EPI) therapeutics market are targeting product regulatory clearances and investment techniques to improve their stake in the market.
Reasons to Buy this Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Exocrine Pancreatic Insufficiency (EPI) Therapeutics market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Exocrine Pancreatic Insufficiency (EPI) Therapeutics market
➡Leading company profiles reveal details of key Exocrine Pancreatic Insufficiency (EPI) Therapeutics market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Exocrine Pancreatic Insufficiency (EPI) Therapeutics market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
Buy This Complete Business Report With Flat 30% Off @ https://www.coherentmarketinsights.com/insight/buy-now/2020
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Exocrine Pancreatic Insufficiency (EPI) Therapeutics Industry Impact
Chapter 2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics (Volume and Value) by Type
2.3 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics Sales, Consumption, Export, Import by Regions
Chapter 5 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Analysis
Chapter 6 East Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Analysis
Chapter 7 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Analysis
Chapter 8 South Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Analysis
Chapter 9 Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Analysis
Chapter 10 Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Analysis
Chapter 11 Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Analysis
Chapter 12 Oceania Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Analysis
Chapter 13 South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Exocrine Pancreatic Insufficiency (EPI) Therapeutics Business
Chapter 15 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Forecast (2021-2028)
Chapter 16 Conclusions
Research Methodology….
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837